JP7829171B2 - ミスフォールドｔｄｐ－４３に対する抗体およびその使用方法 - Google Patents

ミスフォールドｔｄｐ－４３に対する抗体およびその使用方法

Info

Publication number
JP7829171B2
JP7829171B2 JP2021533492A JP2021533492A JP7829171B2 JP 7829171 B2 JP7829171 B2 JP 7829171B2 JP 2021533492 A JP2021533492 A JP 2021533492A JP 2021533492 A JP2021533492 A JP 2021533492A JP 7829171 B2 JP7829171 B2 JP 7829171B2
Authority
JP
Japan
Prior art keywords
sequence
seq
cdr
amino acid
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021533492A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022512388A (ja
Inventor
ニール、アール．キャッシュマン
ヨハンネ、カプラン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Promis Neurosciences Inc
Original Assignee
Promis Neurosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Promis Neurosciences Inc filed Critical Promis Neurosciences Inc
Publication of JP2022512388A publication Critical patent/JP2022512388A/ja
Priority to JP2025101407A priority Critical patent/JP2025146838A/ja
Application granted granted Critical
Publication of JP7829171B2 publication Critical patent/JP7829171B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
JP2021533492A 2018-12-14 2019-12-16 ミスフォールドｔｄｐ－４３に対する抗体およびその使用方法 Active JP7829171B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025101407A JP2025146838A (ja) 2018-12-14 2025-06-17 ミスフォールドｔｄｐ－４３に対する抗体およびその使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862779904P 2018-12-14 2018-12-14
US62/779,904 2018-12-14
US201962923789P 2019-10-21 2019-10-21
US62/923,789 2019-10-21
PCT/CA2019/051823 WO2020118458A1 (en) 2018-12-14 2019-12-16 Antibodies to misfolded tdp-43 and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025101407A Division JP2025146838A (ja) 2018-12-14 2025-06-17 ミスフォールドｔｄｐ－４３に対する抗体およびその使用方法

Publications (2)

Publication Number Publication Date
JP2022512388A JP2022512388A (ja) 2022-02-03
JP7829171B2 true JP7829171B2 (ja) 2026-03-13

Family

ID=71076680

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021533492A Active JP7829171B2 (ja) 2018-12-14 2019-12-16 ミスフォールドｔｄｐ－４３に対する抗体およびその使用方法
JP2025101407A Pending JP2025146838A (ja) 2018-12-14 2025-06-17 ミスフォールドｔｄｐ－４３に対する抗体およびその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025101407A Pending JP2025146838A (ja) 2018-12-14 2025-06-17 ミスフォールドｔｄｐ－４３に対する抗体およびその使用方法

Country Status (6)

Country Link
US (1) US12559548B2 (enExample)
EP (1) EP3894433A4 (enExample)
JP (2) JP7829171B2 (enExample)
AU (1) AU2019399680B2 (enExample)
CA (1) CA3123116A1 (enExample)
WO (1) WO2020118458A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230003067A (ko) * 2020-04-29 2023-01-05 더 유니버시티 오브 브리티쉬 콜롬비아 미스폴딩된 tdp-43에 대한 단일쇄 항체 및 인트라바디 그리고 사용 방법
CA3231484A1 (en) 2021-10-01 2023-04-06 Qinwen Mao Pathologic tdp-43 as a biomarker for the diagnosis of tdp-43 proteinopathy
IL316153A (en) * 2022-04-08 2024-12-01 Ac Immune Sa Anti-tdp-43 binding molecules
EP4497826A4 (en) 2022-04-22 2026-03-25 Univ Niigata TDP-43 AGGREGATION SUPPRESSANT AND PHARMACEUTICAL COMPOSITION
AU2024403128A1 (en) * 2023-12-19 2026-06-25 Vectory Therapeutics B.V. Anti-tdp-43 antibodies and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015505665A (ja) 2011-10-28 2015-02-26 バイオジェン アイデック インターナショナル ニューロサイエンス ゲーエムベーハー Ｔｄｐ−４３に特異的な結合分子
WO2018226590A1 (en) 2017-06-05 2018-12-13 The Trustees Of Columbia University In The City Of New York Peptides as biomarkers in the diagnosis, confirmation and treatment of a neurological disorder and immunoprofiling in neurodegenerative disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7910703B2 (en) 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
JP2018503596A (ja) 2014-10-03 2018-02-08 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ Ｔｄｐ−４３の病理学的形態に対する抗体及びその使用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015505665A (ja) 2011-10-28 2015-02-26 バイオジェン アイデック インターナショナル ニューロサイエンス ゲーエムベーハー Ｔｄｐ−４３に特異的な結合分子
WO2018226590A1 (en) 2017-06-05 2018-12-13 The Trustees Of Columbia University In The City Of New York Peptides as biomarkers in the diagnosis, confirmation and treatment of a neurological disorder and immunoprofiling in neurodegenerative disease

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Acta Neuropathologica Communications，2014年，Vol.2, Article No.33，pp.1-9

Also Published As

Publication number Publication date
US12559548B2 (en) 2026-02-24
JP2025146838A (ja) 2025-10-03
CA3123116A1 (en) 2020-06-18
AU2019399680A1 (en) 2021-07-15
US20220056118A1 (en) 2022-02-24
EP3894433A1 (en) 2021-10-20
WO2020118458A1 (en) 2020-06-18
EP3894433A4 (en) 2022-08-31
JP2022512388A (ja) 2022-02-03
AU2019399680B2 (en) 2026-07-23

Similar Documents

Publication Publication Date Title
US12559548B2 (en) Antibodies to misfolded TDP-43 and methods of use
US11214613B2 (en) Epitopes in the RNA recognition motif 1 (RRM1) of TDP-43 and misfolding-selective antibodies thereto
NL2011406C2 (en) Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides.
CN120468431A (zh) 焦谷氨酸淀粉样蛋白-β的抗体及其用途
US20230174630A1 (en) Single chain antibodies and intrabodies to misfolded tdp-43 and methods of use
CA2832391C (en) Means and methods for diagnosing and treating multiple sclerosis
WO2014096321A1 (en) Antibodies specific to tau phosphorylated at serine 422 and uses for the treatment and diagnosis of tauopathies
US20250346655A1 (en) Conformation-specific epitopes in alpha-synuclein, antibodies thereto and methods related thereof
AU2022390134A1 (en) Novel molecules for therapy and diagnosis
US20220218805A1 (en) Conformation-specific epitopes in tau, antibodies thereto and methods related thereof
EP4079758A1 (en) Semg2 antibody and use thereof
US20220242939A1 (en) Antibody directed against the apoe amino-terminal fragment of 12kda
HK40080158A (en) Semg2 antibody and use thereof
NZ615912B2 (en) Means and methods for diagnosing and treating multiple sclerosis

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221215

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240408

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240709

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241008

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241119

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250617

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260114

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260127

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260220

R150 Certificate of patent or registration of utility model

Ref document number: 7829171

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150